Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...
Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.
Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, ...
Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...